Company webinar

Alterity Therapeutics (ASX:ATH)

Watch our webinar with Alterity Therapeutics, featuring Managing Director, CEO Dr David Stamler. A presentation followed by live Q&A with the audience.

Date
August 26, 2026
Time
Where
Online
Entry
Free
Dr David Stamler
Dr David Stamler
Managing Director, CEO, Alterity Therapeutics (ASX:ATH)

About the company

Alterity Therapeutics (ASX: ATH | NASDAQ: ATHE) is a clinical-stage biotech developing ATH434, a potential first-in-class oral therapy for Multiple System Atrophy (MSA) - a fatal, rapidly progressing neurodegenerative disease with no approved disease modifying treatments. Phase 2 data showed statistically significant slowing of disease progression, and the FDA has confirmed the registrational pathway for ATH434, with a single pivotal Phase 3 trial on track to initiate by year-end 2026.

Key topics

  • What is MSA
  • The Science and ATH434
  • Phase 2 Clinical Trial Data
  • The Road to Phase 3
  • Catalysts and Outlook

Watch the recording

More webinars

All webinars →

Go beyond the presentation

Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.

Explore our services →